Implantica has decided to proceed with a private placement of SDRs raising gross proceeds of approximately SEK 600 million - Seite 2

Implantica intends to use the net proceeds from the Private Placement towards the following activities:

• Approximately 45 percent of the proceeds will be used to:
• Speed up commercialization by building up the sales organization in key markets in advance of regulatory approvals and reimbursement
• Eventually explore strategic acquisitions, such as smaller companies selling surgical instruments in selected strategic markets, to expand the network and sales force
• Approximately 30 percent of the proceeds will be used to:
• Expedite bringing the eHealth platform to market
• Expand and enhance the eHealth platform including additional functionality and more treatment fields
• Approximately 25 percent of the proceeds will be used to:
• Develop more eHealth-based products such as new stimulation technology and drug delivery from inside the body

"We look forward to continuing to provide life-changing meaningful solutions for patients and at the same time to have all the attributes to be a great investment opportunity for our shareholders. We show our highest gratitude to our shareholders to be given the opportunity and additional resources to speed-up the commercialization of RefluxStop, which has been progressing since the IPO with both high acceptance by the surgeons as well as presenting excellent long-term results. We are also very excited for our eHealth progress with our platform technology and large patent portfolio as a basis to continue to expand our eHealth functionality and expedite an accelerated process," said Peter Forsell, CEO of Implantica.

The Company believes that using the flexibility provided by a non-pre-emptive placing is the most appropriate transaction structure in order to raise capital in a time- and cost-effective manner, whilst also further diversifying and strengthening the Company's shareholder base.

Through the Private Placement, the Company's share capital will increase by CHF 9,800,000 from CHF 128,923,074 to CHF 138,723,074. The total number of shares will increase by 4,900,000 shares from 109,461,537 to 114,361,537, whereof 58,111,537 are Class A shares represented by SDRs, and 56,250,000 are Class B shares. The Private Placement results in a dilution of approximately 7.1 percent of the share capital and approximately 4.3 percent of the votes.